Tong Ren Tang Technologies Co. Ltd. (HKG:1666)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 4.00B -34.9% |
| Revenue (ttm) | 6.66B -17.0% |
| Net Income | 354.14M -28.9% |
| EPS | 0.28 -28.9% |
| Shares Out | 1.28B |
| PE Ratio | 11.28 |
| Forward PE | 7.62 |
| Dividend | 0.21 (6.73%) |
| Ex-Dividend Date | Jun 16, 2026 |
| Volume | 1,029,500 |
| Open | 3.130 |
| Previous Close | 3.130 |
| Day's Range | 3.090 - 3.150 |
| 52-Week Range | 2.955 - 4.950 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 5.38 (+72.44%) |
| Earnings Date | Aug 28, 2026 |
About HKG:1666
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through three segments: The Company; Tong Ren Tang Chinese Medicine; and Others. The company develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products. It also offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics.... [Read more]
Financial Performance
In 2025, HKG:1666's revenue was 6.48 billion, a decrease of -10.69% compared to the previous year's 7.26 billion. Earnings were 396.28 million, a decrease of -24.06%.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for 1666 stock is "Strong Buy." The 12-month stock price target is $5.38, which is an increase of 72.44% from the latest price.
News
Chinese Medicine Firm Seeks Elusive Elixir Of IPO Success
The healthcare services arm of the Tong Ren Tang group enjoys a high-profile TCM brand, but its profit margins lag far behind industry peers Key Takeaways: Tong Ren Tang Healthcare ranks as China's bi...